It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services faces Senate scrutiny due to his ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

Ana Botin, executive chair of Spanish bank Santander has denied reports that the company is considering leaving the British ...

Emma Raducanu has claimed that she will have no pressure heading into the clash against Iga Swiatek in Round 3 of the Australian Open 2025. Raducanu defeated Amanda Aminis Listen to Story Raducanu ...

GSK Plc ’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in 2024 ...

Under boss Dame Emma Walmsley, GSK has been focusing on “bolt-on” takeovers of biotech firms in targeted areas. GSK is the UK’s second biggest drugmaker after ASTRAZENECA. THE hospitality ...

GSK's purchase of the group further expands its oncology portfolio, which has grown in recent years under chief executive Emma Walmsley amid investor pressure. It acquired TESARO, developer of ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.